Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca announced that a TR-1 notification submitted by The Capital Group Companies, Inc. was provided in error and advised shareholders to disregard it. Instead, they should refer to the TR-1 notification announced on 21 August 2025. This clarification helps maintain accurate shareholder information and ensures transparency in AstraZeneca’s communications.
The most recent analyst rating on (GB:AZN) stock is a Hold with a £110.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
Average Trading Volume: 2,360,079
Technical Sentiment Signal: Strong Buy
Current Market Cap: £184B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.